BioNano Genomics (BNGO) Gets a Buy Rating from Maxim Group

By Jason Carr

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BioNano Genomics (BNGOResearch Report), with a price target of $3.00. The company’s shares closed last Monday at $0.88, close to its 52-week low of $0.50.

According to, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -21.4% and a 25.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Hancock Jaffe Laboratories, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNano Genomics with a $3.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.00 and a one-year low of $0.50. Currently, BioNano Genomics has an average volume of 4.07M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.